Drug intelligence / Profile preview

Bicalutin

Development stage: Unknown
Lead developer: Dr. Pfleger
Modality: Small Molecules
Administration: Oral

Overview

Bicalutin is a non-steroidal antiandrogen medication containing the active ingredient bicalutamide, a small molecule that acts as a competitive antagonist at the androgen receptor. Developed and marketed by Dr. Pfleger Arzneimittel, it is used for the treatment of prostate cancer, specifically advanced and locally advanced hormone-dependent prostate carcinoma. By blocking the binding of male sex hormones (androgens) to their receptors, Bicalutin inhibits the growth of hormone-dependent prostate cancer cells. It is available in 50 mg and 150 mg tablet strengths for oral administration, often used in combination with LHRH analogs or as monotherapy depending on the disease stage.

Brand names: Bicalutin
Other names: bicalutamide

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Bicalutin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bicalutin.

Explore the full profile